Q

Quest Diagnostics

Operates nationwide clinical laboratory testing

Phlebotomist Group Lead

Full-TimePosted on 10/16/2026
$17.71 - $26.56/hr+ Annual performance bonus
Senior
Richmond, VA, USA
HybridTravel to multiple locations is required, including coverage with minimal notice.
Medical, Clinical & VeterinaryDiagnostics & Laboratory Professionals

About the job

Requirements
  • Seven years of phlebotomy experience, including pediatric, geriatric, and capillary collections.
  • Keyboard and data-entry experience.
  • Availability to work flexible hours based on staffing needs, including weekends, holidays, on-call shifts, and overtime.
  • Reliable transportation, a valid driver's license, and a clean driving record, if applicable.
  • Ability to travel and work flexible hours across multiple locations, including covering Patient Service Center, Mobile, Long-Term Care, and In-Office Phlebotomy locations with minimal notice.
  • Ability to lift and carry objects ranging from 1 to 40 pounds, with assistance for objects exceeding 41 pounds.
  • Ability to sit or stand for long periods and perform repetitive hand tasks throughout the day.
  • Ability to use a phone and PC extensively and perform fine dexterity tasks.
  • Ability to communicate effectively in English.
  • Ability to provide quality, error-free work in a fast-paced environment and work independently with minimal on-site supervision.
  • Excellent phlebotomy skills, including pediatric and geriatric collections.
  • Ability to communicate openly and transparently with peers, supervisors, and patients, adapt to change, and understand the business.
  • Ability to handle multiple priorities in a high-volume setting and make decisions based on established procedures using good judgment.
  • High school diploma or equivalent.
  • Phlebotomy certification is preferred and required in certain states, including California, Nevada, Washington, and Louisiana.
Responsibilities
  • Collect specimens according to established procedures, including drug screens, biometric screenings, and insurance examinations.
  • Administer oral solutions according to established training.
  • Research test and client information and verify written and electronic orders using laboratory technology systems or the directory of services.
  • Complete accurate data-entry requirements, including patient registration, test-order entry from requisitions or databases, and management of standing orders.
  • Enter billing information and collect payments when required, safeguarding assets and credit-card information.
  • Process specimens by labeling, centrifuging, splitting, and freezing them as required by test orders.
  • Perform assigned clerical duties, including data entry, inventory, stocking supplies, and answering phones.
  • Follow departmental policies, protocols, and procedures, and ensure staff members follow instructions.
  • Verify patient demographic information and initials, and obtain the patient's signature after venipuncture to confirm tubes were labeled in the patient's presence and correctly named.
  • Assist with compiling and submitting monthly statistics and data.
  • Maintain required phlebotomy logs, including maintenance and temperature logs, according to schedule.
  • Complete training courses and stay current on phlebotomy techniques.
  • Travel to Territory Manager meetings when held off-site or outside the normal shift.
  • Participate in special projects and teams.
  • Stay current on company communications and help distribute technical information to the workgroup.
  • Perform Point of Care testing at designated sites and complete required training and competency evaluations according to standard operating procedures.
  • Mentor and support new employees in their transition to the Patient Service Center work environment and established procedures.
  • Assist with periodic inventory counts and preparing schedules for the assigned workgroup or Patient Service Centers.
  • Communicate professionally with clients to resolve or refer issues, document problems, and report critical issues as they occur.
  • Ensure staff follow safety precautions, including wearing a clean buttoned lab coat, gloves, and face shield when required.
  • Assist supervisors with implementing standard operating procedures and distributing technical information and communications in accordance with company guidelines.
  • Keep facilities neat, clean, and in good repair, and notify the supervisor about needed repairs or maintenance.
  • Act as a coach, mentor, instructor, and resource advisor for new employees; serve as an on-site staff contact and provide regular input to the supervisor.
  • Provide effective onboarding services to new clients.
  • Partner with the supervisor to support setting up new Patient Service Center and In-Office Phlebotomy locations.
  • Step in for a PSR III and lead one or more PSRs on site.
  • Support patient inquiries from the website, Office of Chairman, and Managed Care as needed.
  • Support the Problem Resolution Line and respond to field requests regarding patient recollection when needed.
  • Provide input on PSR performance evaluations.
Desired Qualifications
  • Medical assistant or paramedic training.
  • At least five years of experience in a Patient Service Center or In-Office Phlebotomy environment.
  • Customer service experience in a retail or service environment.

About the company

Quest Diagnostics provides clinical laboratory testing and diagnostic services. It processes patient samples across a network of laboratories to run a broad menu of 3,000+ tests, including cancer diagnostics and anatomical pathology, and delivers interpretive reports through its medical staff. Tests are performed at its patient service centers, esoteric and rapid-response labs, and outpatient facilities, with results shared with clinicians via connected data systems. What sets Quest Diagnostics apart is its scale and scope: the world’s largest clinical lab network, the broadest test menu, a large team of MDs and PhDs for interpretation, and leadership in cancer diagnostics and pre-employment drug testing, plus extensive clinical trials testing. Its goal is to empower healthcare providers and patients with actionable diagnostic insights to identify, treat, and manage disease, inspire healthy behaviors, and improve health outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Secaucus, New Jersey

Founded

1967

Get referred to Quest Diagnostics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apple Health users will order Quest tests later in 2026, expanding direct-to-consumer reach.
  • Quest’s consumer-health business reached $250 million in 2025 and management targets 30% 2026 growth.
  • Quest will launch Roche pTau217 and its new multi-biomarker AD-Detect panel in Q4 2026.

What critics are saying

  • CMS cuts lab reimbursement up to 15% on January 1, 2027, hitting CMS revenue.
  • Quest faces NLRB case 14-CA-378210 over alleged discharge and coercive statements in St. Louis.
  • Repeated PAMA cuts and commoditized testing can squeeze Quest into a low-margin processing utility.

What makes Quest Diagnostics unique

  • Quest serves half of U.S. physicians and hospitals through 2,000 service centers.
  • Quest built a consumer-health platform with Apple Health, Oura, Hims & Hers, and Function Health.
  • Quest leads blood-based Alzheimer’s diagnostics with AD-Detect and Roche pTau217 launches in 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • 401(k) Company Match
  • Performance Bonus
  • Employee Stock Purchase Plan
  • Tuition Reimbursement
  • Wellness Program
  • Paid Vacation
  • Paid Holidays
  • Flexible Work Hours
  • 401(k) Retirement Plan

Company News

Yahoo Finance
Sep 22nd, 2026
Quest Diagnostics drops 5% as US cuts lab test reimbursement rates by 15%

Quest Diagnostics stock fell 5.1% on Tuesday after the Centers for Medicare and Medicaid Services announced it would cut reimbursement rates for lab work by up to 15%, effective 1 January 2027. CMS disclosed it has been paying approximately 16% more for lab tests than private insurers. The rate cuts could save taxpayers $1 billion annually but will reduce Quest's revenue. The company derives about 11% of its revenue from CMS reimbursement. If rates decrease by the full 15%, Quest's annual revenue would drop by 1.65%. Successive 15% annual reductions are possible through 2029, meaning a worst-case revenue reduction of slightly less than 5%. The company had warned in its SEC filing that Medicare and Medicaid rate changes posed risks to its business.

Citybiz
Sep 14th, 2026
Quanterix names yuri Fesko chief medical officer as diagnostics business expands.

Quanterix names yuri Fesko chief medical officer as diagnostics business expands. September 14, 2026 Dr. Yuri Fesko Quanterix Corporation has appointed Dr. Yuri Fesko chief medical officer, adding an experienced diagnostics executive as the company prepares for a broader market launch of its Lucent AD(R) Complete Alzheimer's disease test and advances regulatory work for its HD-X instrument. Fesko will provide medical and clinical leadership across the Nasdaq-listed precision biomarker company, working with its Diagnostics, Scientific, R&D, Regulatory and Commercial teams. He will be based at Quanterix's headquarters in Billerica, Massachusetts. The newly created role comes as Quanterix works to expand its diagnostics business and move more of its biomarker technologies into clinical applications. President and CEO Everett Cunningham said Fesko's background in clinical affairs and precision medicine will support both the commercialization of Lucent AD Complete and the company's planned IVD filing for HD-X. "As we prepare for the broader market launch of our Lucent AD Complete five biomarker test for Alzheimer's Disease, we welcome Dr. Yuri Fesko to Quanterix in an important new role to support our efforts to efficiently scale our expansion in diagnostics," Cunningham said. Fesko most recently served as chief medical officer at Quest Diagnostics, where he oversaw Medical Affairs, Clinical Development, Analytics and Public Health. He also served as the medical lead supporting the company's Quality and Regulatory functions and provided senior medical leadership for pathology and dermatopathology. His experience spans the development and implementation of precision medicine strategies in oncology, metabolic disease, neurology and consumer health. He has worked with health systems, pharmaceutical and biotechnology companies, and physician organizations to integrate precision diagnostics into clinical practice and clinical trials. Fesko also brings experience supporting FDA submissions, clinical development programs, companion diagnostic strategies and reimbursement planning. Those capabilities are relevant as Quanterix works to translate its biomarker research technologies into regulated diagnostic products and expand their use in clinical settings. One immediate priority is Lucent AD Complete, Quanterix's five-biomarker blood test for Alzheimer's disease. The company is preparing for a broader market launch of the test while simultaneously advancing the IVD regulatory filing for its HD-X instrument, making medical, regulatory and commercialization coordination a central part of Fesko's mandate. Cunningham said Fesko's ability to work across medicine, diagnostics, analytics and business strategy will support the company's efforts to build its Diagnostics business and broaden the clinical applications of its technology. Quanterix develops precision biomarker technologies designed to detect and quantify biological markers at very low concentrations. Its Simoa(R) platform provides high-sensitivity biomarker measurement in blood and other fluids, supporting applications across disease research, diagnostics and drug development. The company's technology portfolio has also expanded through its acquisition of Akoya Biosciences. Quanterix Spatial solutions provide high-plex quantitative protein analysis in tissue at single-cell resolution, adding spatial biology capabilities alongside its existing fluid biomarker technologies. Quanterix also operates Accelerator Laboratory services, providing researchers with additional capabilities for moving biomarker discoveries toward diagnostic applications. Together, those businesses give the company a platform spanning biomarker measurement, spatial analysis and laboratory services as it increases its focus on precision diagnostics. Fesko earned both his bachelor's degree and Doctor of Medicine from Case Western Reserve University and completed a fellowship at University Hospitals of Cleveland. He is board-certified in internal medicine, hematology and medical oncology. His appointment adds senior clinical leadership at a point when Quanterix is managing both product commercialization and regulatory execution. As the company expands beyond research applications, Fesko will help coordinate the medical evidence, regulatory strategy and clinical adoption required to move its biomarker technologies more broadly into diagnostic workflows.

PR Newswire
Sep 9th, 2026
Apple Health app users to order lab tests from Quest Diagnostics for $119

Apple Health app users in the United States will be able to purchase laboratory tests from Quest Diagnostics directly through the app later this year. Apple announced the update at its September event. Users can buy a Quest laboratory panel featuring over 50 biomarkers for $119. The panel assesses cardiometabolic health and organ function, including biometric readings for blood pressure, height, weight, and waist and hip circumferences. Customers can schedule blood draws and biometric readings at approximately 2,000 Quest patient service centres across the US. Results will appear in the Apple Health app shortly after testing. Quest collaborates with third-party providers to review test orders and discuss results at no additional charge.

Yahoo Finance
Sep 8th, 2026
Quest Diagnostics CEO sells 10,000 shares for $2.4M under pre-arranged trading plan

J.E. Davis, CEO and President of Quest Diagnostics, sold 10,000 shares of the diagnostic testing company for $2.4 million on 1 September 2026, according to an SEC Form 4 filing. The shares were sold at $242.72 each under a Rule 10b5-1 trading plan. Following the transaction, Davis retains 122,423 shares in the company, valued at $28.9 million. The sale occurred after Quest Diagnostics shares delivered a 32% total return over the preceding 12 months. Quest Diagnostics reported revenue of $11.6 billion and net income of $1.1 billion over the trailing twelve months. The company has a market capitalisation of $26.4 billion.

Ticker Report
Sep 5th, 2026
Man Group plc Makes New $495,000 Investment in Quest Diagnostics Incorporated $DGX

Man Group plc purchased a new position in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,336 shares of the medical research company’s stock, valued at approximately $495,000. Several other hedge funds […]